Novo Nordisk, BioNxt Solutions, BioNTech – How to heal your portfolio with the 2025 healthcare revolution

Novo Nordisk – Between records and setbacks

Novo Nordisk posted strong growth in the first quarter. Revenue jumped 18% to DKK 78.1 billion, while operating profit rose by as much as 20%. The popular diabetes and obesity drugs Ozempic and Wegovy are driving growth. Despite these solid figures, management remains cautious and has lowered its annual forecast slightly. The reason for this is the increasing number of low-cost generic drugs, which are entering the lucrative US market in particular and significantly increasing competitive pressure.

The obesity drug Wegovy remains the growth engine, contributing to an impressive 83% growth in the first quarter. Nevertheless, earnings fell just short of analyst expectations. This is primarily due to unapproved copies, known as compounds, that are manufactured in pharmacies in the US. Novo Nordisk has the US courts on its side, as it has successfully secured supplies. New study data is encouraging. Higher doses led to an average weight loss of 21% in studies, with a third of participants losing more than 25%.

The Company's pipeline remains promising. Recently presented data on active ingredients such as the combination CagriSema and Amycretin point to even stronger treatment options. Amycretin showed over 24% weight reduction in early tests. To translate research into products more quickly, Novo Nordisk has reorganized its development structure. Three therapy areas are now supported by specialized AI teams. At the same time, the Company is investing heavily in production capacity and preparing to launch an oral obesity treatment. This diversity is intended to secure its leading position in the growing market. Since June 25, the share price has been moving sideways and is currently trading at EUR 59.24.

BioNxt Solutions – New platforms for targeted drug delivery

BioNxt Solutions is working on a promising technology for precision oncology. Its new Targeted Drug Delivery System concentrates highly effective chemotherapeutic agents specifically in the tumor area, and quickly neutralizes free drug molecules to protect healthy tissue. Laboratory tests suggest a potential tenfold increase in therapeutic efficacy, accompanied by enhanced protection of healthy cells. The platform is compatible with over 100 established cancer drugs, including those that have previously been too toxic for systemic use. This positions BioNxt not as a competitor, but as a potential collaboration partner for established pharmaceutical companies in a market that is expected to grow to USD 98 billion by 2030.

At the same time, BioNxt is advancing its sublingual melt film platform. The product candidate, BNT23001, also known as cladribine, is being prepared for a bioequivalence study in the second half of 2025 for the treatment of multiple sclerosis. This dosage form may be particularly beneficial for patients with swallowing difficulties. In addition, the Company is evaluating its oral thin film technology for use with GLP-1 receptor agonists such as semaglutide. This market has massive growth potential. The goal here is to create a patient-friendly alternative to injections or large tablets, which could improve treatment adherence. If the Company succeeds in achieving success in this area faster than Novo Nordisk, a partnership would be a win-win situation for both companies.

BioNxt is clearly committed to cooperation. For its oncology platform, the Company is planning joint developments, licensing agreements, or supply partnerships with pharmaceutical and generic drug manufacturers. This approach is intended to reduce development risks and costs and accelerate regulatory processes. The focus on delivery technologies for proven active ingredients, rather than in-house drug development, underscores this partner-oriented business strategy. Successes in the pipeline, particularly in the planned bioequivalence study for BNT23001, are expected to further increase the attractiveness of such partnerships. The share is currently trading at EUR 0.336.

BioNTech – Between lab ambition and a declining balance sheet

The Mainz-based biotech icon is at a turning point. After the pandemic boom, the quarterly figures are now dominated by red numbers. Revenue of EUR 183 million and a loss of EUR 416 million highlight the challenges. The reason for this is not operational weakness, but rather a deliberate change of course. Over half a billion euros was invested in research in the first quarter alone. With EUR 15.9 billion in cash, the Company still has significant financial flexibility, but it is clear that COVID-19 revenues are dwindling. The annual forecast of EUR 1.7 to 2.2 billion underscores this transition phase.

Where is BioNTech investing? The fight against cancer remains the main focus. The bispecific antibody BNT327, developed in collaboration with Bristol Myers Squibb, leads the pipeline, flanked by promising candidates such as BNT111 against melanoma. At the same time, Africa's first mRNA production facility is being built in Rwanda, a strategic move. The modular "BioNTainers" will not only produce COVID vaccines, but also malaria and tuberculosis vaccines locally in the future. The goal is to open up new markets and strengthen global resilience far beyond pandemics.

Despite the losses, analysts see light on the horizon and the majority recommend buying. The high valuation is based on future expectations rather than current earnings. The CureVac takeover and the billion-dollar deal with Bristol Myers consolidate the Company's technological leadership, but also increase the pressure to turn the more than 20 clinical programs into marketable therapies. For investors, this means that those who believe in mRNA beyond COVID see substantial potential here. But patience is a must. The stock is currently trading at EUR 95.40.

The healthcare industry in 2025 is a force field of innovation and systemic pressure that offers investment opportunities. Novo Nordisk continues to dominate the obesity/diabetes market with blockbusters such as Wegovy, but faces increasing pressure from generics and needs to commercialize its pipeline quickly to maintain its leadership. BioNxt Solutions scores with revolutionary delivery systems, particularly in targeted oncology and with patient-friendly melt films, and consistently focuses on collaborations to share risks and open up markets. BioNTech is undergoing a challenging yet necessary transformation. Massive investments in the cancer immunotherapy pipeline and global mRNA expansion are intended to replace dwindling COVID revenues, but require patience from investors.